Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Lancet (London, England)（2023）
摘要
National Institutes of Health.
更多查看译文
关键词
chimpanzee adenovirus type,marburg adenovirus,vaccine,immunogenicity,first-in-human,open-label,dose-escalation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要